Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2348MR)

This product GTTS-WQ2348MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2348MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10983MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ5866MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ12698MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ4336MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ15383MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ5675MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ13304MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ13233MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-05082566
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW